🏛️ Verified NIH Record • Updated 2026-02-10
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS (NCT06325748)
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Senti Biosciences
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Who can join: Review the eligibility criteria below.
Location: UCLA Medical Center — Los Angeles, California
Age range: 18 Years to 74 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- UCLA Medical Center — Los Angeles, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Mayo Clinic — Jacksonville, Florida
- TriStar Bone Marrow Transplant — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Methodist Healthcare — San Antonio, Texas
- Royal Prince Alfred Hospital — Camperdown, New South Wales
- Peter MacCallum Cancer Center — Melbourne, Victoria
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML/MDS
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML — The Bronx, New York
- CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) — Memphis, Tennessee
Explore by condition: All AML/MDS clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.